




page 53 post column
 University of Minnesota
 Department of Chemistry
 VAC-300
 User: rhshms
 Sample: 20
 Spin rate: 24
 Date: Aug. 25, 1998
 Solvent: CDCl3
 File: 2001
 Starting time: 12:58:29
 Completion time: 13:05:15
 Total acq. time 1 minute
 UNITYplus-300 "vac300"
 Ambient temperature
 PULSE SEQUENCE
 Relax. delay 1.500 sec
 Pulse 90.0 degrees
 Acq. time 2.000 sec
 Width 5998.8 Hz
 16 repetitions
 OBSERVE H1, 299.9572854 MHz
 DATA PROCESSING
 Line broadening 0.1 Hz
 Ft size 65536





flashed

University of Minnesota
Department of Chemistry
VAC-300

User: rtherph

Sample: 28

Spin rate: 24

Date: Jan. 15, 1999

Solvent: CDCl3

File: 2801

Starting time: 15:41:50

Completion time: 15:49:18

Total acq. time 1 minute

UNITYplus-300 "vac300"

Ambient temperature

PULSE SEQUENCE

Relax. delay 1.500 sec

Pulse 90.0 degrees

Acq. time 2.000 sec

Width 5998.8 Hz



16 repetitions

OBSERVE H1, 299.9572854 MHz

DATA PROCESSING



Line broadening 0.1 Hz

Ft size 65536




4


3-3 product
 University of Minnesota
 Department of Chemistry
 VAC-300
 User: rhscjd
 Sample: 11
 Spin rate: 24
 Date: Feb. 25, 1999
 Solvent: CDCl3
 File: 1101
 Starting Time: 13:24:24
 Completion Time: 13:31:04
 Total acq. time 1 minute
 UNITYplus-300 "vac300"
 Ambient temperature
 PULSE SEQUENCE
 Relax. delay 1.500 sec
 Pulse 90.0 degrees
 Acq. time 2.000 sec
 Width 5998.8 Hz
 16 repetitions
 OBSERVE HI, 299.9572854 MHz
 *DATA PROCESSING
 Line broadening 0.1 Hz
 FT size 65536





10 9 8 7 6 5 4 3 2 1 ppm
 0.84 0.12 0.10 0.13 0.17 4.39 -0.07
 89.55
 1.49
 -0.12






5



6











9

p171-p1
 User: rhswllc
 Date: Feb. 15, 2000
 Solvent: CDCl3
 File: p171-p1
 Starting Time: 13:42:01
 Completion Time: 13:42:33
 Total acq. time 1 minute
 UNITYplus-500 "f1q"
 Ambient temperature
 PULSE SEQUENCE
 Relax. delay 1.500 sec
 Pulse 90.0 degrees
 Acq. time 1.892 sec
 Width 8000.0 Hz
 8 repetitions
 OBSERVE H1, 499.8671218 MHZ
 DATA PROCESSING
 Line broadening 0.1 Hz
 FT size 32768





13









11





12








14



p175-2p
 User: r1sw11
 Date: Feb. 19, 191999
 Solvent: CDCl3
 File: p175-2p
 Starting Time: 15:06:51
 Completion Time: 15:08:05
 Total acq. time 1 minute
 UNITYplus-500 "fid"
 Ambient temperature
 PULSE SEQUENCE
 Relax delay 1.500 sec
 Pulse 90.0 degrees
 Acq. time 2.001 sec
 Width 5997.9 Hz
 16 repetitions
 OBSERVE H1, 299.8882224 MHz
 DATA PROCESSING
 Line broadening 0.2 Hz
 FT size 32768



SUPPLEMENTARY MATERIAL FOR

the
communication
entitled

**Formal Cycloaddition Reactions of Vinylogous Amides
with α,β -Unsaturated
Iminiums. A Strategy for Constructing Piperidinyl Heterocycles.**

Richard P. Hsung*, Lin-Li Wei, Heather M. Sklenicka, Christopher J. Douglas,¹
Michael J. McLaughlin, Jason A. Mulder, and Letitia J. Yao²

Department of Chemistry, University of Minnesota, Minneapolis, MN 55455

General Procedure for the Reactions of 1,3-Diketones or Vinylogous Amides with α,β -Unsaturated Iminiums.

The appropriate starting enal (1-2 mmol) (filtered through silica gel if it is from commercial sources) was dissolved in anhydrous EtOAc (dried over CaH₂ quickly, filtered through celite, and stored over molecular sieves), and 2.0 eq piperidine was added dropwise via syringe. The solution was cooled to -10 °C (ice in acetone), and 2.0 eq of acetic anhydride was added carefully dropwise. After stirring for an additional 5 minutes at -10 °C, the iminium mixture was sealed under a blanket of anhydrous nitrogen and heated at 85 °C (sand bath) for 1 h. The warm iminium solution was then transferred quickly via a cannula to a solution of appropriate starting diketones or vinylogous amides (0.4 to 0.5 mole% to the starting enal) in anhydrous toluene (the ratio of EtOAc to toluene was usually 2:3). The reaction mixture was again sealed under a blanket of nitrogen and heated at 150 °C in a sand bath for 18-96 h. The reaction progress was monitored by using TLC analysis (mostly 50% ethyl acetate in hexane or pure EtOAc. When the reaction was completed, the mixture was concentrated under reduced pressure, and the desired cyclized product was isolated using silica gel column chromatography (gradient eluent: ethyl acetate in hexane, 5-100%).

Characterizations for Isolated Products:

For Compound 1.

R_f = 0.46 (50% EtOAc in hexane);

¹H NMR (300 MHz, CDCl₃) δ 1.39 (s, 6H) 1.96 (m, 2H) 2.38 (m, 4H) 5.23 (d, 1H, J = 9.9 Hz) 6.40 (d, 1H, J = 10.2 Hz);

¹³C NMR (300 MHz, CDCl₃) δ 20.7, 28.4, 28.7, 29.7, 36.5, 79.8, 110.61, 115.9, 122.9, 171.7, 195.0;

IR (neat) cm⁻¹ 3054 (m), 2974 (s), 1724 (m), 1651 (s), 1588 (s), 1411 (s), 1267 (m);

mass spectrum (EI): m/e (%relative intensity) 178 (13) M⁺, 163 (100), 135 (5), 121 (6), 107 (5), 79 (10);

For Compound 2.

R_f = 0.47 (50% EtOAc in hexane);

¹H NMR (300 MHz, CDCl₃) δ 0.96 (t, 3H, J = 3.6 Hz), 1.44 (m, 2H), 1.53 (m, 2H), 1.66 (m, 2H), 1.97 (m, 2H), 2.37 (m, 2H), 4.90 (m, 1H), 5.28 (dd, 1H, J = 3.3, 9.9 Hz), 6.45 (dd, 1H, J = 1.5, 9.9);

¹³C NMR (300 MHz, CDCl₃) δ 13.9, 17.6, 20.6, 28.3, 36.4, 37.9, 77.5, 111.4, 117.5, 117.9, 172.7, 195.0;

IR (neat) cm⁻¹ 3078(w), 2959 (s), 2935 (s), 2873 (m), 1650 (s), 1594 (m), 1221 (m);

mass spectrum (EI): m/e (%relative intensity) 192 (7) M⁺, 150 (12) 149 (100), 107 (7), 77 (5);

C₁₂H₁₆O₂ (192)

For Compound 3.

R_f = 0.53 (50% EtOAc in hexane);

¹H NMR (300 MHz, CDCl₃) δ 1.50 (m, 2H), 1.82 (m, 2H), 1.99 (sext, 4H, J = 6.6 Hz), 2.09 (m, 2H), 2.37 (t, 4H, J = 6.6 Hz), 5.26 (d, 1H, J = 9.9 Hz), 6.43 (d, 1H, J = 9.9 Hz);

¹³C NMR (50 MHz, CDCl₃) δ 20.7, 23.5, 28.8, 36.5, 40.7, 83.4, 90.5, 116.5, 121.7, 172.4, 194.9;

IR (neat) cm⁻¹ 2959 (s), 1641 (s), 1607 (s), 1588 (s);

mass spectrum (EI): m/e (%relative intensity) 204 (20) M⁺, 175 (100), 148 (9), 91 (9), 55 (8);

For Compound 4.

R_f = 0.50 (50% EtOAc in hexane);

¹H NMR (300 MHz, CDCl₃) δ 1.39 (m, 2H), 1.53 (m, 4H), 1.61 (m, 2H), 1.84 (m, 2H), 1.95 (sext, 2H, J = 6.6 Hz), 2.37 (t, 2H, J = 4.8 Hz), 2.42 (d, 2H, J = 4.8 Hz), 5.27 (d, 1H, J = 10.2 Hz), 6.72 (d, 1H, J = 10.2);

¹³C NMR (50 MHz, CDCl₃) δ 20.7, 20.9, 21.0, 25.1, 28.6, 36.5, 80.7, 111.3, 116.4, 122.3, 171.8, 195.0;

IR (neat) cm⁻¹ 2930 (s), 1651 (s), 1611 (s);

mass spectrum (EI): m/e (%relative intensity) 218 (35) M⁺, 175 (100), 162 (10), 91 (10), 41 (9);

For Compound **5**.

R_f = 0.47 (50% EtOAc in hexane);

¹H NMR (200 MHz, CDCl₃) δ 1.41 (s, 3H), 1.48 (s, 3H), 2.57 (dd, 1H, J = 4.6, 17.6 Hz), 2.87 (dd, 1H, J = 5.8, 17.6 Hz), 5.27 (d, 1H, J = 10 Hz) 5.42 (dd, 1H, J = 4.2, 1.88 Hz), 6.32 (d, 1H, J = 10 Hz), 7.40 (m, 5H);

¹³C NMR (300 MHz, CDCl₃) δ 28.5, 28.6, 34.6, 80.9, 100.4, 116.5, 123.2, 126.0, 128.6, 128.7, 138.3, 165.1, 165.2;

IR (neat) cm⁻¹ 3063 (s), 3035 (s), 2976 (s), 2929 (s), 1709 (s), 1644 (m), 1423 (m), 1147 (m);

mass spectrum (EI): m/e (%relative intensity) 256 (13) M⁺, 241 (88), 152 (7), 135 (100), 104 (35), 77 (30), 51 (13);

For Compound **6a**.

R_f = 0.15 (50% EtOAc in hexane);

¹H NMR (300 MHz, CDCl₃) δ 1.03 (s, 6H), 1.27 (s, 6H), 2.18 (s, 2H), 2.22 (s, 2H), 4.4.1 (brs, 1H), 5.00 (dd, 1H, J = 1.8, 9.9 Hz), 6.51 (d, 1H, J = 9.9 Hz);

¹³C NMR (75 MHz, CDCl₃) δ 26.4, 28.3, 31.7, 42.5, 50.3, 53.7, 110.4, 117.6, 120.4, 157.9, 190.5;

IR (neat) cm⁻¹ 3241s, 3196w, 2939s, 2870w, 1634s, 1585s, 1526s, 1457s, 1364m, 1246w, 1142w;

mass spectrum (EI): m/e (%relative intensity) 205 (10) M⁺, 190 (100), 134 (15), 106 (10);

For Compound **6b**.

R_f = 0.50 (50% EtOAc in hexane);

¹H NMR (300 MHz, CDCl₃) δ 1.08 (s, 6H), 1.47 (s, 6H), 2.26 (s, 3H), 2.29 (s, 2H), 2.38 (s, 2H), 5.34 (d, 1H, J = 9.8 Hz), 6.47 (d, 1H, J = 9.8 Hz);

¹³C NMR (75 MHz, CDCl₃) δ 27.4, 28.0, 29.4, 34.6, 45.1, 50.4, 59.1, 116.2, 116.8, 131.1, 150.7, 174.9, 193.8;

IR (neat) cm⁻¹ 2958s, 2929m, 2870w, 1697s, 1643s, 1575s, 1467m, 1413m, 1364m, 1265s, 1216s, 1172m, 1142w;

mass spectrum (EI): m/e (%relative intensity) 247 (5) M⁺, 232 (15), 190 (100), 174 (4), 134 (5);

For Compound **12**.

R_f = 0.70 (EtOAc);

¹H NMR (300 MHz, CDCl₃) δ 1.30 (s, 6H), 1.84 (quint, 2H, J = 6.3 Hz), 2.31 (t, 2H, J = 6.5 Hz), 2.39 (t, 2H, J = 6.1 Hz), 4.64 (s, 2H), 5.02 (d, 1H, J = 9.8 Hz), 6.67 (d, 1H, J = 9.8 Hz), 7.20 (d, 2H, J = 7.2 Hz), 7.28 (t, 1H, J = 7.8 Hz), 7.35 (t, 2H, J = 7.5 Hz);

¹³C NMR (75 MHz, CDCl₃) δ 21.6, 28.9, 35.5, 42.5, 47.8, 59.5, 118.4, 121.1, 125.2, 127.2, 128.9, 138.5, 160.7, 169.0, 191.9;

IR (neat) cm^{-1} 3056w, 2948m, 2919m, 2870w, 1604s, 1530s, 1432s, 1349m, 1167w, 1093w;
mass spectrum (EI): m/e (%relative intensity) 267 (12) M^+ , 252 (100), 190 (5), 133 (5);

For Compound 13.

$R_f = 0.45$ (10% MeOH in EtOAc);

^1H NMR (300 MHz, CDCl_3) δ 0.90 (t, 3H, $J = 7.2$ Hz), 1.40 (m, 3H), 1.68-1.97 (m, 3H), 2.42 (m, 4H), 3.98 (m, 1H), 4.37 (d, 1H, $J = 17.0$ Hz), 4.80 (d, 1H, $J = 17.0$ Hz), 5.21 (dd, 1H, $J = 4.9, 9.8$ Hz), 6.73 (d, 1H, $J = 9.8$ Hz), 7.29 (m, 5H);

^{13}C NMR (75 MHz, CDCl_3) δ 14.1, 17.0, 21.3, 26.6, 35.5, 37.4, 52.8, 60.1, 108.5, 113.7, 120.9, 125.9, 127.7, 129.1, 136.7, 160.4, 191.8;

IR (neat) cm^{-1} 2955m, 2932m, 2871w, 1711w, 1659w, 1611s, 1529s, 1496w, 1477w, 1449m, 1421m, 1342m, 1319m, 1177m,;

mass spectrum (EI): m/e (%relative intensity) 281 (9) M^+ , 238 (35), 190 (12), 161 (4), 119 (4), 91 (100);

For Compound 14.

$R_f = 0.47$ (EtOAc);

^1H NMR (300 MHz, CDCl_3) δ 0.08 (s, 3H), 0.09 (s, 3H), 0.91 (s, 9H), 1.07 (s, 6H), 1.31 (s, 6H), 2.21 (s, 2H), 2.41 (s, 2H), 3.45 (t, 2H, $J = 6.6$ Hz), 3.69 (t, 2H, $J = 6.6$ Hz), 4.95 (d, 1H, $J = 9.6$ Hz), 6.58 (d, 1H, $J = 9.6$ Hz);

^{13}C NMR (75 MHz, CDCl_3) δ -5.5, 18.3, 26.0, 26.1, 28.4, 32.3, 40.8, 46.3, 49.6, 59.1, 63.4, 106.7, 118.3, 121.1, 159.9, 191.5 ;

IR (neat) cm^{-1} 2958s, 2929m, 2860w, 1590s, 1521s, 1432s, 1359w, 1334w, 1147w, 1088w, 840w;

mass spectrum (EI): m/e (%relative intensity) 363 (18) M^+ , 348 (100), 234 (35), 216 (20), 91 (20);

For Compound 15.

$R_f = 0.52$ (EtOAc);

^1H NMR (300 MHz, CDCl_3) δ 0.07 (s, 3H), 0.08 (s, 3H), 0.91 (s, 9H), 1.06 (s, 6H), 1.57 (m, 6H), 1.68 (m, 2H), 1.89 (m, 2H), 2.22 (s, 2H), 2.43 (s, 2H), 3.47 (t, 2H, $J = 6.6$ Hz), 3.64 (t, 2H, $J = 6.6$ Hz), 5.37 (d, 1H, $J = 9.6$ Hz), 6.65 (d, 1H, $J = 9.6$ Hz);

^{13}C NMR (75 MHz, CDCl_3) δ -5.4, 18.3, 21.6, 25.3, 25.8, 28.6, 32.4, 35.2, 41.4, 45.8, 49.0, 61.1, 63.4, 107.9, 115.9, 115.9, 119.4, 159.7, 191.6;

IR (neat) cm^{-1} 2929s, 2860m, 1614s, 1526m, 1467w, 1427s, 1329w, 1250w, 1237w, 1103m, 1049w, 837s;

mass spectrum (EI): m/e (%relative intensity) 403 (10) M^+ , 375 (5), 344 (100), 288 (9), 258 (24), 189 (10), 133 (9);

For Compound 16.

R_f = 0.65 (EtOAc);

¹H NMR (300 MHz, CDCl₃) δ 1.35 (s, 6H), 2.04 (s, 3H), 4.60 (s, 2H), 5.13 (d, 1H, J = 9.9 Hz), 5.54 (s, 1H), 6.50 (d, 1H, J = 9.9 Hz), 7.20 (d, 2H, J = 7.2 Hz), 7.28 (t, 1H, J = 7.8 Hz), 7.35 (t, 2H, J = 7.5 Hz);

¹³C NMR (75 MHz, CDCl₃) δ 20.5, 29.2, 47.5, 58.8, 92.8, 96.3, 118.2, 123.7, 125.6, 127.3, 128.9, 137.5, 153.2, 161.0, 162.1;

IR (neat) cm⁻¹ 3047w, 3027w, 2958m, 2919m, 2870w, 1682s, 1526s, 1486s, 1452s, 1344m, 1157w, 1049w;

mass spectrum (EI): m/e (%relative intensity) 281 (10) M⁺, 266 (100), 194 (5), 175 (5), 128 (5);

For Compound 17.

R_f = 0.68 (EtOAc);

¹H NMR (300 MHz, CDCl₃) δ 0.87 (t, 3H, J = 7.2 Hz), 1.22 (m, 1H), 1.39 (m, 2H), 1.66 (m, 1H), 2.09 (s, 3H), 4.10 (m, 1H), 4.41 (d, 1H, J = 17.4 Hz), 4.66 (d, 1H, J = 17.4 Hz), 5.28 (dd, 1H, J = 5.4, 9.9 Hz), 5.69 (s, 1H), 6.60 (d, 1H, J = 9.9 Hz), 7.21 (d, 2H, J = 7.3 Hz), 7.29 (t, 1H, J = 7.9 Hz), 7.36 (t, 2H, J = 7.7 Hz);

¹³C NMR (75 MHz, CDCl₃) δ 14.0, 16.8, 20.5, 37.7, 52.5, 59.4, 93.6, 95.8, 116.5, 120.7, 126.2, 127.7, 129.0, 136.2, 153.2, 161.3, 162.2;

IR (neat) cm⁻¹ 2958m, 2929m, 2870w, 1684s, 1643m, 1521s, 1491m, 1452m, 1329w, 1260w;

mass spectrum (EI): m/e (%relative intensity) 295 (11) M⁺, 252 (100), 204 (30), 175 (30), 146 (5), 121 (5);

For Compound 18.

R_f = 0.61 (EtOAc);

¹H NMR (300 MHz, CDCl₃) δ 1.58 (m, 6H), 1.64 (m, 2H), 1.98 (m, 2H), 2.07 (s, 3H), 4.64 (s, 2H), 5.59 (s, 1H), 5.65 (d, 1H, J = 10.0 Hz), 6.61 (d, 1H, J = 10.0 Hz), 7.21 (d, 2H, J = 8.1 Hz), 7.30 (t, 1H, J = 8.7 Hz), 7.36 (t, 2H, J = 8.1 Hz);

¹³C NMR (75 MHz, CDCl₃) δ 20.5, 21.2, 25.0, 35.8, 47.1, 61.2, 93.5, 96.6, 118.9, 125.7, 127.2, 128.6, 128.8, 137.7, 153.7, 160.9, 162.2;

IR (neat) cm⁻¹ 2929m, 2850w, 1682s, 1644m, 1521s, 1481m, 1452m, 1339w, 1246w, 1019w, 955w;

mass spectrum (EI): m/e (%relative intensity) 321 (4) M⁺, 319 (89), 318 (100), 290 (9), 262 (100), 250 (11), 191 (21), 165 (10), 115 (35);

For Compound **22**.

R_f = 0.53 (50% EtOAc in hexane);

¹H NMR (300 MHz, CDCl₃) δ 1.67 (d, 3H, J = 1.2 Hz), 1.91 (d, 3H, J = 1.2 Hz), 2.46 (m, 4H), 2.65 (m, 4H), 4.11 (d, 1H, J = 9.6 Hz), 4.34 (brd, 1H, J = 9.6 Hz);

¹³C NMR (75 MHz, CDCl₃) δ 18.5, 24.9, 25.9, 26.7, 34.2, 120.7, 122.8, 135.1, 177.7, 201.9;

IR (neat) cm⁻¹ 2918 (s), 1693 (s), 1668 (s), 1614 (s), 1339 (s);

mass spectrum (EI): m/e (%relative intensity) 229 (25) M⁺, 189 (100);

For Compound **28**.

R_f = 0.32 (10% MeOH in EtOAc);

¹H NMR (300 MHz, CDCl₃) δ 0.91 (t, 3H, J = 7.3 Hz), 1.35-1.80 (m, 4H), 2.43 (m, 2H), 2.59 (m, 2H), 4.18 (m, 1H), 4.38 (d, 1H, J = 16.1 Hz), 4.67 (d, 1H, J = 16.1 Hz), 5.10 (dd, 1H, J = 4.4, 9.8 Hz), 6.37 (d, 1H, J = 9.8 Hz), 7.24-7.40 (m, 5H);

¹³C NMR (75 MHz, CDCl₃) δ 14.1, 16.7, 25.2, 33.9, 36.8, 51.2, 59.3, 110.1, 116.2, 118.5, 126.7, 128.0, 129.1, 135.4, 173.5, 196.8;

IR (neat) cm⁻¹ 2956w, 2929s, 2870m, 1710w, 1656m, 1625s, 1586m, 1561s, 1495s, 1452m, 1408w, 1364m, 1311m, 1257w, 1234w, 1030w;

mass spectrum (EI): m/e (%relative intensity) 267 (5) M⁺, 266 (15), 224 (100), 247 (9), 133 (3);